These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21609230)

  • 21. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents.
    Tomany SC; Wang JJ; Van Leeuwen R; Klein R; Mitchell P; Vingerling JR; Klein BE; Smith W; De Jong PT
    Ophthalmology; 2004 Jul; 111(7):1280-7. PubMed ID: 15234127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists--comments on the current therapy for neovascular AMD].
    Pauleikhoff D; Bornfeld N; Gabel VP; Holz F; Roider H; ; ;
    Klin Monbl Augenheilkd; 2005 May; 222(5):381-8. PubMed ID: 15912454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment for atrophic macular degeneration.
    Meleth AD; Wong WT; Chew EY
    Curr Opin Ophthalmol; 2011 May; 22(3):190-3. PubMed ID: 21427574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic treatment of atrophic age-related macular degeneration.
    Mata NL; Vogel R
    Curr Opin Ophthalmol; 2010 May; 21(3):190-6. PubMed ID: 20216419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study.
    Sunness JS; Applegate CA; Bressler NM; Hawkins BS
    Retina; 2007 Feb; 27(2):204-10. PubMed ID: 17290203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SPA-2: semiology for phenotyping AMD: atrophic AMD].
    Tahiri Joutei Hassani R; Le Tien V; Canoui-Poitrine F; Atmani K; Querques G; Sterkers M; Massamba N; Coscas G; Soubrane G; Bastuji-Garin S; Souied EH
    J Fr Ophtalmol; 2011 Feb; 34(2):83-90. PubMed ID: 21281987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement factor H polymorphism in age-related macular degeneration.
    Narayanan R; Butani V; Boyer DS; Atilano SR; Resende GP; Kim DS; Chakrabarti S; Kuppermann BD; Khatibi N; Chwa M; Nesburn AB; Kenney MC
    Ophthalmology; 2007 Jul; 114(7):1327-31. PubMed ID: 17306880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes and mechanism of action for rheopheresis treatment of age-related macular degeneration (AMD).
    Pulido J; Sanders D; Winters JL; Klingel R
    J Clin Apher; 2005 Oct; 20(3):185-94. PubMed ID: 15892078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carotenoids and co-antioxidants in age-related maculopathy: design and methods.
    Neelam K; Hogg RE; Stevenson MR; Johnston E; Anderson R; Beatty S; Chakravarthy U
    Ophthalmic Epidemiol; 2008; 15(6):389-401. PubMed ID: 19065432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
    Palanki MS; Akiyama H; Campochiaro P; Cao J; Chow CP; Dellamary L; Doukas J; Fine R; Gritzen C; Hood JD; Hu S; Kachi S; Kang X; Klebansky B; Kousba A; Lohse D; Mak CC; Martin M; McPherson A; Pathak VP; Renick J; Soll R; Umeda N; Yee S; Yokoi K; Zeng B; Zhu H; Noronha G
    J Med Chem; 2008 Mar; 51(6):1546-59. PubMed ID: 18311895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
    Michels S; Rosenfeld PJ
    Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statin and aspirin therapy are associated with decreased rates of choroidal neovascularization among patients with age-related macular degeneration.
    Wilson HL; Schwartz DM; Bhatt HR; McCulloch CE; Duncan JL
    Am J Ophthalmol; 2004 Apr; 137(4):615-24. PubMed ID: 15059698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Age-related macular degeneration].
    Benyelles N; Soubrane G
    Rev Prat; 2006 Jun; 56(11):1194-201. PubMed ID: 16903520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current drug patenting for retinal diseases: beyond VEGF inhibitors.
    Mucke HA; Mucke PM
    IDrugs; 2010 Jan; 13(1):30-7. PubMed ID: 20024845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome analysis in clinical trial design for acute stroke: physicians' attitudes and choices.
    Savitz SI; Benatar M; Saver JL; Fisher M
    Cerebrovasc Dis; 2008; 26(2):156-62. PubMed ID: 18560219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation treatment for age-related macular degeneration.
    Silva RA; Moshfeghi AA; Kaiser PK; Singh RP; Moshfeghi DM
    Semin Ophthalmol; 2011 May; 26(3):121-30. PubMed ID: 21609224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retinal pseudocysts in age-related geographic atrophy.
    Cohen SY; Dubois L; Nghiem-Buffet S; Ayrault S; Fajnkuchen F; Guiberteau B; Delahaye-Mazza C; Quentel G; Tadayoni R
    Am J Ophthalmol; 2010 Aug; 150(2):211-217.e1. PubMed ID: 20537310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Age-related macular degeneration in Singapore.
    Cheng CL; Saw SM; Pang CE; Chee C
    Singapore Med J; 2009 Feb; 50(2):126-31. PubMed ID: 19296026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 40. Overview of progress in the epidemiology of age-related macular degeneration.
    Klein R
    Ophthalmic Epidemiol; 2007; 14(4):184-7. PubMed ID: 17896295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.